The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Duration of Vimseltinib Treatment
Timeframe: Baseline up to 12 months
Time to Discontinuation of Vimseltinib
Timeframe: Baseline to Discontinuation (Estimated up to 12 months)